Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950699 | 0.97 | TLR7 (0.65) | TLR7TLR8 | |
| Trifluoroacetic Acid SCHEMBL5349765 | 0.95 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL1952404 | 0.94 | TLR7 (0.59) | TLR7 | |
| SCHEMBL20806194 | 0.93 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL22522221 | 0.93 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL5747604 | 0.93 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL3865268 | 0.92 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL13937528 | 0.91 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL5750921 | 0.91 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL13937519 | 0.91 | TLR7 (0.59) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507237-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068233-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136801-A1 | Novel Compounds | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| CN-1355701-A | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2002-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136801-A1 | Novel Compounds | C1R, RB1, CNKSR1 | TLR7 3566/4885TLR8 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.